Daniel L. Geisler

Daniel L. Geisler

Auto-generated profile, based on publicly available information

Daniel L. Geisler

Department of Pathology, University of Pittsburgh Medical Center-Presbyterian, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2022 in Urology Case Reports
Verified
Journal Article
Open access
DGDaniel Geisler
Daniel Geisler
FAFawaz Almutairi
Fawaz Almutairi
IJIvy John
Ivy John
GQGabriela Quiroga-Garza
Gabriela Quiroga-Garza
MYMichelle Yu
Michelle Yu
SBSheldon Bastacky
Sheldon Bastacky
Juxtaglomerular cell tumors (JGCTs) are rare, typically benign neoplasms; only rare cases are clinically or histologically malignant. We herein report the histologic, immunophenotypic, and molecular features of a clinically unsuspected, diagnostically challenging case of malignant JGCT in a 23-year-old man. The diagnosis is confirmed with electron microscopy. The case is notable for its marked mitotic activity, which has not been previously reported in JGCTs, and novel finding of GATA3 immunohistochemical positivity.

10 February 2022 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
DGDaniel L. Geisler
Daniel L. Geisler
RNRichard J. Nestler
Richard J. Nestler
BMBeth L. Mosley
Beth L. Mosley
AWAdrianna L. Walko
Adrianna L. Walko
JCJacqueline M. Cuda
Jacqueline M. Cuda
NON. Paul Ohori
N. Paul Ohori

25 September 2023 in Cancer Cytopathology
Verified
Journal Article
Closed access
DGDaniel L. Geisler
Daniel L. Geisler
MMMason Marshall
Mason Marshall
SBSheldon I. Bastacky
Sheldon I. Bastacky
SKSamer N. Khader
Samer N. Khader

2 March 2024 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
TJTerri E. Jones
Terri E. Jones
DGDaniel L. Geisler
Daniel L. Geisler
SBSwikrity Upadhyay Baskota
Swikrity Upadhyay Baskota
NON. Paul Ohori
N. Paul Ohori
JCJacqueline Cuda
Jacqueline Cuda
SKSamer N. Khader
Samer N. Khader

18 November 2022 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
DGDaniel L. Geisler
Daniel L. Geisler
EFEsra Karslioglu French
Esra Karslioglu French
LYLinwah Yip
Linwah Yip
MNMarina N. Nikiforova
Marina N. Nikiforova
YNYuri E. Nikiforov
Yuri E. Nikiforov
NON. Paul Ohori
N. Paul Ohori

26 April 2021 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
DGDaniel Geisler
Daniel Geisler
MFMegan Culler Freeman
Megan Culler Freeman
GRGlenn J Rapsinski
Glenn J Rapsinski
SWSarah E Wheeler
Sarah E Wheeler
Objectives: Serologic assay performance studies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-​2) in pediatric populations are lacking, and few seroprevalence studies have routinely incorporated orthogonal testing to improve accuracy. Methods: Remnant serum samples for routine bloodwork from 2,338 pediatric patients at UPMC Children’s Hospital of Pittsburgh were assessed using the EUROIMMUN Anti-SARS-CoV-2 ELISA IgG (EuroIGG) assay. Reactive cases with sufficient volume were also tested using 3 additional commercial assays. Results: Eighty-five specimens were reactive according to the EuroIGG, yielding 3.64% (95% confidence interval [CI], 2.91%-4.48%) seropositivity, of which 73 specimens had sufficient remaining volume for confirmation by orthogonal testing. Overall, 19.18% (95% CI, 10.18%-28.18%) of samples were positive on a second and/or third orthogonal assay. This 80.82% false positivity rate is disproportionate to the expected false positivity rate of 50% given our pediatric population prevalence and assay performance. Conclusions: In pediatric populations, false-positive SARS-CoV-2 serology may be more common than assay and prevalence parameters would predict, and further studies are needed to establish the performance of SARS-CoV-2 serology in children.